TLR4 and neoplasm: Subsequent advancements in this formulation were achieved by incorporating two distinct adjuvants (i.e., TLR4 and TLR9 agonists) and protein antigens, resulting in robust anti-tumor efficacy in multiple murine tumor models [15].